Welcome to our dedicated page for Kodiak Sciences SEC filings (Ticker: KOD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Kodiak Sciences Inc. (Nasdaq: KOD) SEC filings, offering insight into how the precommercial retina-focused biotechnology company reports its activities to regulators. Kodiak Sciences develops biologic therapeutics for retinal vascular diseases and macular edema secondary to inflammation (MESI), and its filings reflect the progress and funding of these programs.
Investors can review Form 8-K current reports where Kodiak discloses material events, such as quarterly financial results and business highlights, or the terms and completion of public offerings of common stock. For example, a December 18, 2025 Form 8-K describes the underwriting agreement and closing of an 8,000,000-share public offering that generated gross proceeds of approximately $184 million before expenses.
Through its shelf registration statement on Form S-3 and related prospectus supplements, Kodiak outlines how it may issue securities to finance its late-stage clinical programs, including Phase 3 studies like GLOW2, DAYBREAK, PEAK and PINNACLE. Additional filings, such as quarterly and annual reports when available, typically provide more detail on research and development expenses, cash position and the status of clinical trials for tarcocimab, KSI-501 and KSI-101.
On Stock Titan, users can view Kodiak’s latest SEC submissions as they are posted to EDGAR and use AI-powered tools to summarize complex documents. These tools can help explain offering terms, highlight key clinical and financial disclosures, and surface information on topics such as capital raising, research spending and trial milestones relevant to KOD.
Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson reported an exercise-and-sell transaction involving company stock. On April 2, 2026, he exercised stock options to acquire 30,000 shares of Common Stock at an exercise price of $1.04 per share. The option was fully vested and scheduled to expire on June 22, 2026.
On the same date, he sold a total of 30,000 Common shares in multiple open-market transactions at weighted-average prices of $39.14, $40.29, $40.88, and $41.77 per share. These sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After these transactions, Borgeson directly holds 183,316 shares of Kodiak Sciences Common Stock.
Kodiak Sciences Inc. was reported as having 609,806 shares beneficially owned by Point72-affiliated reporting persons. The filing, a Schedule 13G, shows the holders — Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen — have a 1.0% ownership stake as of the close of business on April 1, 2026.
The statement notes shared voting and dispositive power of 609,806 shares and that the reporting persons directly own no shares; a Joint Filing Agreement is attached as Exhibit 99.1.
Kodiak Sciences Inc. files its annual report describing an advanced retinal disease drug pipeline and significant business risks. The company focuses on its Antibody Biopolymer Conjugate platform and three late-stage candidates: Zenkuda (tarcocimab), KSI-501 and KSI-101 for diabetic eye disease, wet AMD, retinal vein occlusion and inflammation-driven macular edema.
Multiple Phase 3 programs, including GLOW1, GLOW2, BEACON and DAYLIGHT, met primary endpoints, while DAYBREAK, PEAK and PINNACLE remain ongoing with topline data expected between 3Q 2026 and 2Q 2027. Kodiak also discloses substantial doubt about its ability to continue as a going concern and highlights dependence on additional financing, regulatory approvals and successful commercialization.
Kodiak Sciences reported fourth quarter and full-year 2025 results alongside major clinical progress in its retina pipeline. The Phase 3 GLOW2 trial in diabetic retinopathy showed Zenkuda achieved a ≥2-step DRSS improvement in 62.5% of patients versus 3.3% on sham, with an 85% reduction in sight‑threatening complications and a favorable safety profile. These data, together with prior studies, support plans for a multi‑indication BLA submission.
The company strengthened its balance sheet with a December 2025 equity offering of 8 million shares at $23.00 per share, generating net proceeds of $173.0 million, and ended 2025 with $209.9 million in cash and cash equivalents, which it believes funds operations into 2027. Net loss was $56.7 million, or $1.04 per share, for the fourth quarter and $4.32 per share for the full year, driven mainly by higher R&D spending on Phase 3 programs.
Kodiak Sciences Chairman and CEO Victor Perlroth exercised stock options for 300,000 shares of Common Stock at an exercise price of $1.0400 per share. These options were fully vested at the time of exercise. Following the transaction, he directly holds 2,395,538 shares of Common Stock. No open-market sales were reported in this filing, and the derivative position tied to this specific option grant has been fully converted into common shares.
Kodiak Sciences reported positive topline results from GLOW2, its second Phase 3 study of Zenkuda (tarcocimab tedromer) in diabetic retinopathy. In GLOW2, 62.5% of Zenkuda-treated patients achieved at least a 2-step improvement on the Diabetic Retinopathy Severity Scale at Week 48, compared with 3.3% on sham, meeting the primary endpoint with high statistical significance.
Zenkuda also cut the risk of prespecified sight-threatening complications, such as proliferative diabetic retinopathy or center-involving diabetic macular edema, by 85% versus sham through Week 48 (2.4% versus 15.8%). The drug was well-tolerated, with low rates of common ocular adverse events, no intraocular inflammation, and no retinal vasculitis observed.
The company states that the combined GLOW1 and GLOW2 results support a multi-indication BLA-ready profile for Zenkuda across diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration, and it intends to accelerate its BLA submission plans while advancing additional Phase 3 programs based on its ABC platform.
Kodiak Sciences Inc. reported that Chairman and CEO Victor Perlroth received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $25.0000 per share and expire on March 17, 2036.
The award is performance-based. Vesting will be determined by the 30-day average stock price as of June 30, 2027, defined as the Performance Criteria Achievement Date. If the average price is less than $25.00, none of the options vest; at or above $25.00, one-third vests; above $30.00, two-thirds vests; and above $35.00, all 175,000 options vest, subject to Perlroth continuing as a service provider on that date.
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen reported beneficial ownership of Kodiak Sciences Inc. common stock amounting to 2,166,929 shares, or 3.5% of the company’s outstanding shares as of December 31, 2025.
The filing states that Point72 Asset Management has investment and voting power over shares held by an investment fund it manages, with Point72 Capital Advisors as its general partner and Mr. Cohen controlling both entities. The ownership percentage is based on 61,048,428 Kodiak shares outstanding, reflecting recent offerings and previously reported outstanding shares. The reporting persons note they are not holding the securities for the purpose of changing or influencing control of Kodiak Sciences.
Kodak Sciences Inc. large shareholder D. Victor Perlroth, M.D. filed an amended Schedule 13G/A reporting his beneficial ownership of the company’s common stock as of December 31, 2025. He reports beneficial ownership of 6,504,427 shares, representing 9.9% of Kodiak’s outstanding common stock.
The filing explains this stake includes shares held directly, options exercisable within 60 days, shares held by a family foundation, and shares subject to a voting agreement and proxy where he has voting but not investment power. The percentage is based on 61,758,454 shares outstanding as of December 31, 2025.